Main Newsletter
Mastery Series
Therapy Series
 

Letter From The Editor

Editor's Note, DCMS #212

Patients often have to deal with problems we never think of and that makes it hard for them to manage their diabetes. This becomes most important when our patients are insulin users, especially if they have tactile problems or arthritis or joint...


Letter from the Editor, #752

The diabetes drug arena is getting more crowded by the day as new classes of drugs like SGLT-2 inhibitors and


Editor's Note, GLP-1 Agonist Special Edition, October 2014

I was in a doctor's office last week and reached into a drawer to get a pen and, lo and behold, I came out with one of those old metal GLP-1 promotional pens. It was silver with orange yellow and blue-green strips, and felt really good in my...



Editor's Note, SGLT-2 Inhibitors Special Edition, October 2014

Sometimes it seems as if we don't talk about an organ or a problem until we have a medication to treat it. For years we didn't consider the kidney as a problem area for diabetes. It was not until we identified the SGLT-1 and -2 receptors that we...


Editor's Note, DCMS #211

Each week there seem to be articles, studies, and clinical treatises that draw a link between diabetes and cardiovascular disease. If you look through all these documents, the benchmark for measurement always seems to be A1c. However, if you were...


Letter from the Editor, #751

There is some interesting research going on at the University of Missouri about high protein breakfasts that actually delivers a profound message for a reason...


Editor's Note, Insulin Special Edition, October 2014

We have added five totally new classes of non-insulin medications for the treatment of diabetes and so sometimes the reasons to even try insulin make no sense to many of us. However, when we identify patients that have severe cases of...


Editor's Note, DCMS #210

This past weekend I was in Lexington, Kentucky to visit my father and sisters. While I was there, I saw a commercial for a heart institute and they mentioned that heart disease was the number one killer in America today. I would have to agree that...


Letter from the Editor, #750: ACO Update

Two years ago the Affordable Care Act brought about the beginning of ACO's (accountable care organizations). These organizations were created to bring quality of care into play for patients and to reward the best care providers with financial...


Editor's Note, DCMS #209

When we were kids, we used to play a game called Red Light/Green Light, and the goal was to sneak up on the "it" person without them catching your moves. In this week's Homerun Slides series, we bring you a way to use this game


Letter from the Editor, #749

This week we find that a lot of information is coming out the EASD meeting in Vienna, and much of it has to do with


Editor's Note, DCMS #208

The FDA works really hard these days to come up with new brand names that will lessen the chance of drug choice confusion. Often times we wonder how they can come up with these names and what meaning they have. With this in mind, this week's...


Letter from the Editor, #748

For the past 18 months we have been providing you with a monthly newsletter with special features focused on GLP-1 analogs. These newsletters have provided information...


Editor's Note, GLP-1 Agonists Special Editions, September 2014

There has been a lot going on with drugs in the GLP-1 agonist class over the past few months. First we added Tanzeum (albiglutide) as a once-a-week drug. Then the new Bydureon pen was introduced, and finally, Lilly got their once-weekly...


Editor's Note, DCMS #207

In 1969, the group Santana first recorded the song "Evil Ways" with these lines, "You've got to change your evil ways, baby ... You've got to change, baby, And every word that I say is true...." It seems that when it comes...


Letter from the Editor, #747:

This was a busy week in the GLP-1 arena. An FDA advisory panel last week overwhelmingly recommended approval of Novo Nordisk's latest weight-loss drug, Saxenda. This medication, which is liraglutide 3 mg, was recommended as an adjunct to diet and...


Editor's Note, DCMS #206

When Al Mann first said he was going to develop an inhaled insulin, many thought he was beating a dead horse after the collective experiences with Exubera. They forgot that Al had already built the most successful pump company of all times, and...


Editor's Note, SGLT-2 Inhibitor Special Edition, September 2014

As new medications for diabetes come to market there is always a question as to how well they will work when added to other medications. This month, we have a slide presentation from the ADA, outlining the rationale for mating DPP-4...


Letter from the Editor #746

This week we have an item about the increased use of gastric sleeve for weight reduction and the reversal of diabetes. This newer procedure is actually...


Editor's Note, Insulin Special Edition, September 2014

This month's edition of the Insulin Practice series is full of great information about new insulins that we will be able to use in the near future. These products will make it easier for all of us to develop better treatment plans for our patients,...


Editor's Note, DCMS #205

This week there has been a lot of cycling on TV, the Vuelta de Espana, Tour of Alberta, and the Tour of Britain. In addition, in our area many riders are training for the upcoming 6GAP competition in Georgia. Whether you look at the pros or at...


Letter from the Editor #745:

If you attended the recent AADE meeting in Orlando and stopped by to visit our booth, you would have had an opportunity to meet with the developer and provider of our Diabetes In Control


Editor's Note, DCMS #204

I met a patient last Wednesday who had just turned 74 and has been living with type 1 diabetes for over 35 years. He was in fantastic physical condition. However, he had been referred to me because his glucose levels were becoming erratic. We went...


Letter from the Editor, #744

This week I got to see exactly how easy it is for our patients to add extra calories and sugar to their daily routine. It seems that Labor Day is no longer a holiday worthy of a special section in the grocery store for holiday food. On August 14,...


Editor's Note, DCMS #203:

This week in Part 4 of our Homerun Slides series, Dr. Schwartz finishes up by looking at the treatments for LADA, MODY, type 1 and type 2 diabetes, and


Letter from the Editor #743

I am sure many of you have received an email or Facebook post to participate in the ALS Ice Bucket Challenge. I am amazed by the number of people who will actually have a bucket of ice poured over their heads, yet will not take the time to check...


Editor's Note, DCMS #202

MODY, cystic fibrosis, and Wolfram syndrome all have something in common. Believe it or not, they are all a form of diabetes. This week, our Clinical Text from the Handbook of Diabetes looks at


Editor's Note, SGLT-2 Inhibitors, Special Edition, August 2014

Recently JARDIANCE (Empagliflozin) was approved for use, making it the third in this new class of medications. The first two, Invokana (canagiflozin) and Farxiga (dapagliflozin), have had relatively good acceptance into the marketplace especially...


Editor's Note, GLP-1 Agonist August 2014 Special Edition

It is always interesting when two legends in diabetes care sit down and have a conversation about the use of medications in patient care. Usually these thought leaders are early adopters when it comes to using medication combinations for diabetes....


Letter from the Editor, #742

  Sanofi is expanding its insulin portfolio to include the new inhaled insulin, Affreza. While it may not perform in the market at the scale of Lantus, I, for one, am glad that Sanofi is doing this. Five years ago a...


Editor's Note, DCMS #201

Sometimes when we prepare this newsletter, the articles, slides and text all seem to go together. That is very evident when we look at the Clinical Text from Drs. Rudy Bilous and Richard Donnelly, as they talk about


Editor's Note, Insulin Special Edition, August 2014

For years we have had methods for titrating patients with long-acting insulin and there have been very successful patient self-titration algorithms that have proven to work as well as physician-directed dosing. The problem has always been what to...


Letter from the Editor, #741:

Steve, Andrew and I are at the AADE Annual Meeting in Orlando. This meeting has a different flavor than some of the other meetings that we report on. While there are many clinical studies and new drug discoveries presented at the ADA and IDF...


Editor's Note, DCMS #200

For the past four years we have been providing you each week with a "Disaster Averted." These tidbits of experience submitted from your colleagues and from ISMP have pointed to the problems that can occur when we least expect it....


Letter from the Editor #740

Last week I started two patients on V-GO devices. For those of you who are not familiar with the...


Editor's Note, DCMS #199

Sometimes the simplest things can be the hardest to do correctly, and nowhere else could it be more devastating than when a glucagon kit is not used properly. In this week's Disaster Averted, see what could happen


Letter from the Editor, #739

Each year when I talk to educators about the AADE meeting, I often find out that they can't go because it is not their year. For most of them this means that their employer is only sending one or two educators a year and it is not their turn. If...


Editor's Note, DCMS #198

The mixing up of mixed insulins can cause problems for some of our patients especially if they are trying to achieve the best control possible. This week our Disaster Averted looks at


Editor's Note, Special GLP-1 Edition, July 2014

We know that patients lose a great deal of weight after bariatric surgery. Often times some of the weight comes off fast in the beginning and then slowly after that. More importantly these patients have a quick resolution of hyperglycemia and...


Letter from the Editor, #738: Afrezza

After a long battle and comments from many doubters the FDA has approved the inhaled insulin, Afrezza. As soon as the approval came the nay-sayers were quick to remind us of what a failure Exubera had been and there was no way that this new inhaled...



Navigate through our listing of Letter From The Editor articles here.
Next Last

560 Total articles for Letter From The Editor


Browse our other news categories below.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Looking for a particular Newsletter Issue? Click Here


Cast Your Vote
Are your patients getting enough glucose strips to manage their diabetes?


Advertisement


Search Articles On Diabetes In Control